Oldest pages

Jump to navigation Jump to search

Showing below up to 326 results in range #501 to #826.

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

  1. Disposal facility‏‎ (22:02, 24 February 2021)
  2. Dose modifying factor‏‎ (22:03, 24 February 2021)
  3. Exposure pathway‏‎ (22:05, 24 February 2021)
  4. Radiological controlled area‏‎ (22:07, 24 February 2021)
  5. Life Span Study‏‎ (22:10, 24 February 2021)
  6. Detriment‏‎ (19:17, 25 February 2021)
  7. Baseline disease rates‏‎ (19:29, 25 February 2021)
  8. Biomarker‏‎ (19:31, 25 February 2021)
  9. Case–control study‏‎ (19:33, 25 February 2021)
  10. Deterministic effect‏‎ (19:38, 25 February 2021)
  11. Dose and dose-rate effectiveness factor‏‎ (15:54, 26 February 2021)
  12. Dose-threshold hypothesis‏‎ (15:56, 26 February 2021)
  13. Tissue reaction‏‎ (16:00, 26 February 2021)
  14. Doubling dose‏‎ (17:10, 26 February 2021)
  15. Epigenetic effects‏‎ (17:13, 26 February 2021)
  16. Excess absolute risk‏‎ (17:16, 26 February 2021)
  17. Excess relative risk‏‎ (17:25, 26 February 2021)
  18. Homologous recombination‏‎ (17:26, 26 February 2021)
  19. Incidence‏‎ (17:28, 26 February 2021)
  20. Induced genomic instability‏‎ (17:30, 26 February 2021)
  21. Late normal tissue responses‏‎ (17:31, 26 February 2021)
  22. LD 50/30‏‎ (17:33, 26 February 2021)
  23. Lifetime risk estimates‏‎ (17:42, 26 February 2021)
  24. Linear dose response‏‎ (17:43, 26 February 2021)
  25. Linear-quadratic dose response model‏‎ (17:48, 26 February 2021)
  26. Stochastic effect‏‎ (17:58, 26 February 2021)
  27. Nominal risk coefficient‏‎ (19:29, 26 February 2021)
  28. Non-homologous end joining‏‎ (19:30, 26 February 2021)
  29. Non-targeted effects‏‎ (19:31, 26 February 2021)
  30. Normal tissue complication probability‏‎ (19:33, 26 February 2021)
  31. Pooled analysis‏‎ (19:34, 26 February 2021)
  32. Quasi-threshold dose‏‎ (19:35, 26 February 2021)
  33. Reactive oxygen species‏‎ (19:36, 26 February 2021)
  34. Recovery (cellular or tissue)‏‎ (19:38, 26 February 2021)
  35. Reference Animal and Plant‏‎ (19:43, 26 February 2021)
  36. Relative biological effectiveness‏‎ (20:22, 26 February 2021)
  37. Relative risk‏‎ (20:25, 26 February 2021)
  38. Risk coefficient‏‎ (20:30, 26 February 2021)
  39. Targeted effects‏‎ (20:32, 26 February 2021)
  40. Translocation‏‎ (20:33, 26 February 2021)
  41. Radiation source‏‎ (21:04, 26 February 2021)
  42. Dose-response function‏‎ (14:57, 28 March 2021)
  43. Tissue weighting factor‏‎ (21:32, 28 March 2021)
  44. Absorption‏‎ (22:15, 28 March 2021)
  45. Activation‏‎ (22:16, 28 March 2021)
  46. Activity‏‎ (22:19, 28 March 2021)
  47. ICRPædia Guide to the System of Radiological Protection‏‎ (21:44, 3 May 2021)
  48. Active detection system‏‎ (19:35, 11 August 2021)
  49. Additional dose‏‎ (19:36, 11 August 2021)
  50. Allometry‏‎ (19:37, 11 August 2021)
  51. Commissioning‏‎ (19:42, 11 August 2021)
  52. Compartment (environmental)‏‎ (19:44, 11 August 2021)
  53. Accreditation‏‎ (19:45, 11 August 2021)
  54. Backscatter detection system‏‎ (19:48, 11 August 2021)
  55. Clearance‏‎ (19:50, 11 August 2021)
  56. Concentration ratio‏‎ (19:52, 11 August 2021)
  57. Containment‏‎ (19:56, 11 August 2021)
  58. Cosmic radiation‏‎ (19:57, 11 August 2021)
  59. Derived reference level‏‎ (20:00, 11 August 2021)
  60. Derived limit‏‎ (20:00, 11 August 2021)
  61. Derived consideration reference level‏‎ (20:02, 11 August 2021)
  62. Designated area‏‎ (20:03, 11 August 2021)
  63. Evacuation‏‎ (20:07, 11 August 2021)
  64. Exclusion‏‎ (20:08, 11 August 2021)
  65. Exposed individuals‏‎ (20:09, 11 August 2021)
  66. Frequent flyer‏‎ (20:11, 11 August 2021)
  67. Ground-level enhancement‏‎ (20:12, 11 August 2021)
  68. ICRU 4-element tissue‏‎ (20:14, 11 August 2021)
  69. ICRU sphere‏‎ (20:17, 11 August 2021)
  70. Intervention‏‎ (20:18, 11 August 2021)
  71. Licensee‏‎ (20:20, 11 August 2021)
  72. National radon survey‏‎ (20:20, 11 August 2021)
  73. Nominal value‏‎ (20:21, 11 August 2021)
  74. Occupancy factor‏‎ (20:22, 11 August 2021)
  75. Operating management‏‎ (20:23, 11 August 2021)
  76. Potential exposure‏‎ (23:17, 11 August 2021)
  77. Collective dose‏‎ (23:18, 11 August 2021)
  78. Optimisation of protection‏‎ (23:22, 11 August 2021)
  79. Practice‏‎ (23:25, 11 August 2021)
  80. Principles of protection‏‎ (23:25, 11 August 2021)
  81. Radioactive waste‏‎ (23:29, 11 August 2021)
  82. Radiological attack‏‎ (23:30, 11 August 2021)
  83. Radon progeny‏‎ (23:30, 11 August 2021)
  84. Radon-prone area‏‎ (23:31, 11 August 2021)
  85. Redox‏‎ (23:31, 11 August 2021)
  86. Reference value‏‎ (23:34, 11 August 2021)
  87. Safety‏‎ (23:36, 11 August 2021)
  88. Region‏‎ (23:36, 11 August 2021)
  89. Sealed source‏‎ (23:38, 11 August 2021)
  90. Solar flare‏‎ (23:59, 11 August 2021)
  91. Sheltering‏‎ (00:00, 12 August 2021)
  92. Security‏‎ (00:01, 12 August 2021)
  93. Security screening‏‎ (00:02, 12 August 2021)
  94. Protection quantities‏‎ (14:51, 12 August 2021)
  95. Source-related assessment‏‎ (14:53, 12 August 2021)
  96. Superposition principle‏‎ (14:55, 12 August 2021)
  97. Surface contamination‏‎ (14:56, 12 August 2021)
  98. Thoron progeny‏‎ (14:57, 12 August 2021)
  99. Transmission detection system‏‎ (14:59, 12 August 2021)
  100. Trophic level‏‎ (15:00, 12 August 2021)
  101. Waste management‏‎ (15:05, 12 August 2021)
  102. Worker‏‎ (15:08, 12 August 2021)
  103. Working level‏‎ (15:14, 12 August 2021)
  104. Working level month‏‎ (15:17, 12 August 2021)
  105. Adenoma‏‎ (15:24, 12 August 2021)
  106. Air kerma at the patient entrance reference point‏‎ (15:27, 12 August 2021)
  107. Apoptosis‏‎ (15:29, 12 August 2021)
  108. AML/eto‏‎ (15:30, 12 August 2021)
  109. Automatic exposure control‏‎ (15:33, 12 August 2021)
  110. Brachytherapy‏‎ (15:34, 12 August 2021)
  111. Bragg peak‏‎ (15:37, 12 August 2021)
  112. Spread-out Bragg peak‏‎ (15:39, 12 August 2021)
  113. Breakpoint cluster region/abelson‏‎ (15:41, 12 August 2021)
  114. Broad beam therapy irradiation technique‏‎ (15:44, 12 August 2021)
  115. Carers and comforters‏‎ (15:48, 12 August 2021)
  116. Clinical audit‏‎ (15:50, 12 August 2021)
  117. Clonogenic surviving fraction‏‎ (15:52, 12 August 2021)
  118. Cobblestone area forming cell assay‏‎ (15:53, 12 August 2021)
  119. Collimation‏‎ (15:54, 12 August 2021)
  120. Cone beam computed tomography‏‎ (15:56, 12 August 2021)
  121. Dental and maxillofacial imaging‏‎ (16:01, 12 August 2021)
  122. Exposure index‏‎ (16:03, 12 August 2021)
  123. Detector quantum efficiency‏‎ (16:04, 12 August 2021)
  124. Diagnostic reference level‏‎ (16:09, 12 August 2021)
  125. Dose-length product‏‎ (16:11, 12 August 2021)
  126. DRL process‏‎ (16:14, 12 August 2021)
  127. DRL quantity‏‎ (16:18, 12 August 2021)
  128. Exogenous excretion‏‎ (16:19, 12 August 2021)
  129. Functional subunits‏‎ (16:24, 12 August 2021)
  130. Hounsfield unit‏‎ (16:43, 12 August 2021)
  131. Accelerated fractionation‏‎ (16:45, 12 August 2021)
  132. Hyperfractionation‏‎ (16:45, 12 August 2021)
  133. Intensity-modulated radiotherapy‏‎ (16:46, 12 August 2021)
  134. Local DRL‏‎ (16:49, 12 August 2021)
  135. National DRL‏‎ (16:50, 12 August 2021)
  136. DRL value‏‎ (16:51, 12 August 2021)
  137. Mean glandular dose‏‎ (17:28, 12 August 2021)
  138. Multi-detector computed tomography‏‎ (17:31, 12 August 2021)
  139. Multifactorial diseases‏‎ (17:31, 12 August 2021)
  140. Multitarget equation‏‎ (17:37, 12 August 2021)
  141. Noise‏‎ (17:38, 12 August 2021)
  142. Notification value‏‎ (17:41, 12 August 2021)
  143. Nuclear medicine‏‎ (17:42, 12 August 2021)
  144. Molecular imaging‏‎ (17:43, 12 August 2021)
  145. Organ at risk‏‎ (17:44, 12 August 2021)
  146. Oxygen enhancement ratio‏‎ (17:45, 12 August 2021)
  147. Pencil beam‏‎ (17:46, 12 August 2021)
  148. Pilomatricoma‏‎ (17:47, 12 August 2021)
  149. Potential recoverability correction factor‏‎ (17:49, 12 August 2021)
  150. Quality control testing‏‎ (17:51, 12 August 2021)
  151. Radiation-induced second cancer‏‎ (17:52, 12 August 2021)
  152. Radiation-induced secondary malignancy‏‎ (17:53, 12 August 2021)
  153. Ras‏‎ (17:55, 12 August 2021)
  154. Rb‏‎ (17:56, 12 August 2021)
  155. Referrer‏‎ (17:57, 12 August 2021)
  156. Reference air kerma‏‎ (17:59, 12 August 2021)
  157. Regional diagnostic reference levels‏‎ (18:01, 12 August 2021)
  158. Registry‏‎ (18:02, 12 August 2021)
  159. Relative survival‏‎ (18:03, 12 August 2021)
  160. Secondary radiation‏‎ (18:04, 12 August 2021)
  161. Shielding‏‎ (18:05, 12 August 2021)
  162. Size-specific dose estimate‏‎ (18:06, 12 August 2021)
  163. Slice‏‎ (18:07, 12 August 2021)
  164. Standard-size adult‏‎ (18:09, 12 August 2021)
  165. Stem cell‏‎ (18:10, 12 August 2021)
  166. Teratocarcinoma‏‎ (18:11, 12 August 2021)
  167. Time-resolved computed tomography‏‎ (18:13, 12 August 2021)
  168. Tolerance dose‏‎ (18:14, 12 August 2021)
  169. Digital breast tomosynthesis‏‎ (18:15, 12 August 2021)
  170. Treatment preparation in radiotherapy‏‎ (18:16, 12 August 2021)
  171. Typical value‏‎ (18:18, 12 August 2021)
  172. Absorbed fraction‏‎ (18:24, 12 August 2021)
  173. Source region‏‎ (18:27, 12 August 2021)
  174. Activity median aerodynamic diameter‏‎ (18:29, 12 August 2021)
  175. Ambient dose equivalent‏‎ (18:30, 12 August 2021)
  176. Annual intake‏‎ (18:31, 12 August 2021)
  177. Annual limit on intake‏‎ (18:37, 12 August 2021)
  178. Derived air concentration‏‎ (18:41, 12 August 2021)
  179. Biological half-life‏‎ (18:43, 12 August 2021)
  180. Bronchiolar region‏‎ (18:44, 12 August 2021)
  181. Charged-particle equilibrium‏‎ (18:45, 12 August 2021)
  182. Collective effective dose‏‎ (19:04, 12 August 2021)
  183. Compartment‏‎ (19:06, 12 August 2021)
  184. Cross section‏‎ (19:10, 12 August 2021)
  185. Cumulative dose‏‎ (19:11, 12 August 2021)
  186. Deposition‏‎ (19:13, 12 August 2021)
  187. Derived investigation level‏‎ (19:14, 12 August 2021)
  188. Directional dose equivalent‏‎ (19:16, 12 August 2021)
  189. Distribution coefficient‏‎ (19:18, 12 August 2021)
  190. Dose‏‎ (19:22, 12 August 2021)
  191. Absorbed dose‏‎ (19:22, 12 August 2021)
  192. Equivalent dose‏‎ (19:32, 12 August 2021)
  193. Dose commitment‏‎ (19:40, 12 August 2021)
  194. Dose conversion convention‏‎ (19:46, 12 August 2021)
  195. Dose conversion factor‏‎ (19:47, 12 August 2021)
  196. Dose of record (E)‏‎ (19:50, 12 August 2021)
  197. Dose of record Hp (10)‏‎ (19:52, 12 August 2021)
  198. Dose per content function‏‎ (18:26, 17 August 2021)
  199. DS86‏‎ (18:29, 17 August 2021)
  200. DS02‏‎ (18:29, 17 August 2021)
  201. Endosteum‏‎ (18:34, 17 August 2021)
  202. Equieffective dose‏‎ (18:41, 17 August 2021)
  203. Equilibrium equivalent concentration‏‎ (18:43, 17 August 2021)
  204. Equilibrium factor‏‎ (02:06, 18 August 2021)
  205. Excretion rate (instantaneous)‏‎ (02:08, 18 August 2021)
  206. Expanded and aligned radiation field‏‎ (02:11, 18 August 2021)
  207. Expanded radiation field‏‎ (02:12, 18 August 2021)
  208. Exposure (in the context of inhalation)‏‎ (02:14, 18 August 2021)
  209. Extrathoracic airways‏‎ (02:18, 18 August 2021)
  210. Human Respiratory Tract Model‏‎ (02:31, 18 August 2021)
  211. Human Alimentary Tract Model‏‎ (02:33, 18 August 2021)
  212. Gray‏‎ (02:34, 18 August 2021)
  213. Intake‏‎ (02:39, 18 August 2021)
  214. Kerma approximation‏‎ (16:58, 18 August 2021)
  215. Low linear energy transfer radiation‏‎ (17:19, 18 August 2021)
  216. High linear energy transfer radiation‏‎ (17:21, 18 August 2021)
  217. Linear energy transfer‏‎ (17:23, 18 August 2021)
  218. Marrow cellularity‏‎ (17:25, 18 August 2021)
  219. Count median diameter‏‎ (17:38, 18 August 2021)
  220. Mass median diameter‏‎ (17:39, 18 August 2021)
  221. Activity median thermodynamic diameter‏‎ (17:41, 18 August 2021)
  222. Thermodynamic diameter‏‎ (17:42, 18 August 2021)
  223. Measured quantity‏‎ (17:45, 18 August 2021)
  224. Organ/tissue absorbed dose‏‎ (18:14, 18 August 2021)
  225. OLINDA/EXM‏‎ (18:17, 18 August 2021)
  226. Other (systemic) tissues‏‎ (18:23, 18 August 2021)
  227. Particle transport‏‎ (18:24, 18 August 2021)
  228. Dose equivalent‏‎ (18:34, 18 August 2021)
  229. Organ dose equivalent‏‎ (18:36, 18 August 2021)
  230. Personal dose equivalent‏‎ (18:42, 18 August 2021)
  231. Operational quantity‏‎ (18:45, 18 August 2021)
  232. Phantom‏‎ (18:46, 18 August 2021)
  233. Potential alpha energy concentration‏‎ (18:48, 18 August 2021)
  234. Quality factor‏‎ (19:14, 18 August 2021)
  235. Radiation weighting factor‏‎ (19:25, 18 August 2021)
  236. Sievert‏‎ (19:36, 18 August 2021)
  237. Specific effective energy‏‎ (19:40, 18 August 2021)
  238. Dose coefficient‏‎ (18:10, 19 August 2021)
  239. Dose conversion coefficient‏‎ (18:10, 19 August 2021)
  240. Effective dose‏‎ (18:28, 19 August 2021)
  241. Reference individual‏‎ (18:34, 19 August 2021)
  242. Reference parameter value‏‎ (18:35, 19 August 2021)
  243. Reference Person‏‎ (18:39, 19 August 2021)
  244. Reference phantom‏‎ (18:45, 19 August 2021)
  245. Reference worker‏‎ (18:46, 19 August 2021)
  246. S coefficient (radiation weighted)‏‎ (18:57, 19 August 2021)
  247. Specific absorbed fraction‏‎ (19:01, 19 August 2021)
  248. Spongiosa‏‎ (19:04, 19 August 2021)
  249. Thoracic airways‏‎ (19:10, 19 August 2021)
  250. Investigation level‏‎ (19:11, 19 August 2021)
  251. Threshold level‏‎ (19:12, 19 August 2021)
  252. Non-maleficence‏‎ (19:38, 19 August 2021)
  253. Dignity‏‎ (19:51, 19 August 2021)
  254. Beneficence‏‎ (19:51, 19 August 2021)
  255. Prudence‏‎ (19:53, 19 August 2021)
  256. Equity‏‎ (19:55, 19 August 2021)
  257. ALARA‏‎ (20:02, 19 August 2021)
  258. Optimisation‏‎ (20:03, 19 August 2021)
  259. Alimentary tract‏‎ (20:14, 19 August 2021)
  260. Low Earth orbit‏‎ (01:58, 20 August 2021)
  261. Kerma‏‎ (14:12, 7 September 2021)
  262. Employer‏‎ (14:15, 7 September 2021)
  263. Justice‏‎ (14:18, 7 September 2021)
  264. Justification‏‎ (14:18, 7 September 2021)
  265. Kp index‏‎ (14:22, 7 September 2021)
  266. Fairness‏‎ (14:23, 7 September 2021)
  267. Field-size effect (Volume effect)‏‎ (14:23, 7 September 2021)
  268. Flexible tissues‏‎ (14:24, 7 September 2021)
  269. Fluoroscopically guided interventions‏‎ (14:24, 7 September 2021)
  270. Fluence‏‎ (14:24, 7 September 2021)
  271. Fluoroscopically or computed tomography guided interventions‏‎ (14:24, 7 September 2021)
  272. Forbiddenness‏‎ (14:25, 7 September 2021)
  273. Fractional absorption in the gastrointestinal tract‏‎ (14:25, 7 September 2021)
  274. Fractionation‏‎ (14:25, 7 September 2021)
  275. Fractionation and dose delivery patterns‏‎ (14:26, 7 September 2021)
  276. Fractionation sensitivity‏‎ (14:26, 7 September 2021)
  277. Galactic cosmic radiation‏‎ (14:27, 7 September 2021)
  278. Gamma ray‏‎ (14:27, 7 September 2021)
  279. Gastrointestinal syndrome‏‎ (14:27, 7 September 2021)
  280. Gastrulation‏‎ (14:27, 7 September 2021)
  281. Gastroschisis‏‎ (14:28, 7 September 2021)
  282. GATA binding protein 2‏‎ (14:28, 7 September 2021)
  283. Genomic integrity‏‎ (14:28, 7 September 2021)
  284. Rigidity threshold‏‎ (14:29, 7 September 2021)
  285. Graded approach‏‎ (14:29, 7 September 2021)
  286. Graft vs host disease‏‎ (14:29, 7 September 2021)
  287. Granulocyte colony-stimulating factor‏‎ (14:30, 7 September 2021)
  288. Granulocyte-macrophage colony-stimulating factor‏‎ (14:30, 7 September 2021)
  289. Growth factor‏‎ (14:31, 7 September 2021)
  290. Growth fraction‏‎ (14:31, 7 September 2021)
  291. Growth hormone (somatotropin)‏‎ (14:32, 7 September 2021)
  292. X ray‏‎ (14:33, 7 September 2021)
  293. Xerostomia‏‎ (14:33, 7 September 2021)
  294. Value judgement‏‎ (14:33, 7 September 2021)
  295. Valvular heart disease‏‎ (14:34, 7 September 2021)
  296. Virtue ethics‏‎ (14:34, 7 September 2021)
  297. Voxel phantom‏‎ (14:34, 7 September 2021)
  298. Unattached fraction‏‎ (14:55, 7 September 2021)
  299. Unsealed source‏‎ (14:56, 7 September 2021)
  300. Upper reference levels‏‎ (14:56, 7 September 2021)
  301. Uptake‏‎ (14:56, 7 September 2021)
  302. Utilitarian ethics‏‎ (14:57, 7 September 2021)
  303. Cohort study‏‎ (14:21, 3 October 2021)
  304. Lag‏‎ (14:24, 3 October 2021)
  305. Lifetime risk‏‎ (14:28, 3 October 2021)
  306. Absolute risk‏‎ (14:29, 3 October 2021)
  307. Risk‏‎ (14:29, 3 October 2021)
  308. Secretory cells‏‎ (14:31, 3 October 2021)
  309. ICRP Glossary‏‎ (14:37, 3 October 2021)
  310. ICRP Publication 140‏‎ (17:08, 3 October 2021)
  311. ICRP Publication 141‏‎ (17:10, 3 October 2021)
  312. ICRP Publication 142‏‎ (17:10, 3 October 2021)
  313. ICRP Publication 143‏‎ (17:11, 3 October 2021)
  314. ICRP Publication 144‏‎ (17:11, 3 October 2021)
  315. ICRP Publication 145‏‎ (17:12, 3 October 2021)
  316. ICRP Publication 146‏‎ (17:12, 3 October 2021)
  317. ICRP Publication 147‏‎ (17:13, 3 October 2021)
  318. ICRP Publication 148‏‎ (17:13, 3 October 2021)
  319. ICRP Publication 149‏‎ (17:13, 3 October 2021)
  320. ICRP Publication 150‏‎ (17:14, 3 October 2021)
  321. ICRP Publication 151‏‎ (17:14, 3 October 2021)
  322. ICRP Publication 152‏‎ (17:14, 3 October 2021)
  323. ICRP Publication 153‏‎ (17:15, 3 October 2021)
  324. ICRP Publication 154‏‎ (17:15, 3 October 2021)
  325. ICRP Publication 155‏‎ (17:15, 3 October 2021)
  326. ICRP publications‏‎ (17:57, 3 October 2021)

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://icrpaedia.org/Special:AncientPages"